课题基金 / 基金详情

Characterization of Genes and Pathways Conferring Cytoprotective Responses and Validation of Potential Targets that will Enhance First-Line Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer

Characterization of Genes and Pathways Conferring Cytoprotective Responses and Validation of Potential Targets that will Enhance First-Line Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer
赋予细胞保护反应的基因和途径的表征以及将增强非小细胞肺癌一线铂类化疗的潜在靶点的验证
批准号：
274489
负责人：
Leung Ada W
金额：
$10.93万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-11-01 至 2015-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=274489&lang=en
关键词：
Cisplatin Drug Combinations Genome-Wide Screen High Content Screening Analysis Non-Small Cell Lung Cancer Potentiation Real-Time Pcr Small Interfering Rna Synergy Target Validation

项目摘要

项目成果

Leung Ada W的其他基金

相似基金

相关文献

中文摘要
翻译
肺癌是加拿大癌症死亡的主要原因。近年来，越来越多的非吸烟者被诊断患有肺癌，引起了公众的极大关注。非小细胞肺癌（NSCLC）约占80%的病例，其中三分之二的病例
英文摘要
Lung cancer is the leading cause of cancer deaths in Canada. In recent years, more non-smokers are being diagnosed with lung cancer, causing a major public concern. Non-small cell lung cancer (NSCLC) accounts for about 80% of the cases of which two-thirds
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Silencing of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) potentiates cisplatin activity against non-small cell lung cancer
3'-phosphoadenosine 5-phosphosulfate Synthase (PAPSS) - A Potential Therapeutic Target for Non-Small Cell Lung Cancer
海外基金